One68 Global Capital LLC Invests $345,000 in Insmed Incorporated (NASDAQ:INSM)

One68 Global Capital LLC acquired a new position in Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,000 shares of the biopharmaceutical company’s stock, valued at approximately $345,000.

Several other hedge funds and other institutional investors have also modified their holdings of INSM. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in Insmed during the fourth quarter worth $47,000. Smartleaf Asset Management LLC boosted its stake in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in Insmed during the fourth quarter worth $86,000.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00. Following the completion of the sale, the chief executive officer now directly owns 379,534 shares of the company’s stock, valued at approximately $29,580,879.96. This trade represents a 4.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 33,055 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the completion of the sale, the insider now directly owns 138,053 shares of the company’s stock, valued at approximately $11,168,487.70. This represents a 19.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 471,797 shares of company stock valued at $37,621,239 in the last quarter. Company insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on INSM. Royal Bank of Canada restated an “outperform” rating and issued a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Tuesday, April 22nd. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. UBS Group boosted their target price on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, Stifel Nicolaus reduced their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Insmed Trading Up 2.2 %

Shares of INSM opened at $71.40 on Wednesday. The stock has a market capitalization of $12.98 billion, a P/E ratio of -12.77 and a beta of 1.07. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a fifty day simple moving average of $73.86 and a two-hundred day simple moving average of $73.52. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, research analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.